Skip to main content
. 2023 Dec 6;43(4):616–632. doi: 10.1002/npr2.12403

FIGURE 1.

FIGURE 1

Baseline and follow‐up EQ‐5D‐5L in individuals receiving treatment with cannabis‐based medicinal products (CBMPs). Paired data were analyzed using repeated measures ANOVA. *p < 0.050, **p < 0.010, ***p < 0.001 on pairwise analysis against baseline with Bonferroni correction.